Aim Statement

​

To elucidate the scientific rationale and clinical evidence for the use of targeted systemic options in the management of TGCT through consideration of:

​

1. Histologic assessment of postoperative resections of patients who have received the drug with evaluation of the impact over different time points;

2. Early oncologic outcomes such as the percent reduction of tumor volume seen on MRI or the symptomatic benefit to the patient;

3. A review of the role of patient reported outcomes measures in developing patient-centric management approaches; and

4. A Case Series of a set of real-world patients on systemic therapy; including the profile of their clinical presentation over time.